SCHEMBL470341

SCHEMBL470341

CN1Cc2ccccc2C1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.63
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
PKM P14618 2/20 0.53
KDM4E B2RXH2 3/20 0.50
ALOX15 P16050 2/20 0.50
TSHR P16473 2/20 0.50
SIRT1 Q96EB6 1/20 0.50
BRD4 O60885 1/20 0.50
CREBBP Q92793 1/20 0.50
PARP1 P09874 1/20 0.46
RNASEH1 O60930 1/20 0.46
HRH1 P35367 2/20 0.45
SLC6A4 P31645 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 1/20 0.45
XIAP P98170 1/20 0.45
HKDC1 Q2TB90 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29455643 1.00 KMT2A (0.63) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL21212239 0.98 KMT2A (0.61) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL30467294 0.84 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL30467298 0.84 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL20274268 0.80 KMT2A (0.42) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL22612117 0.80 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL22612116 0.80 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL31383689 0.80 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL25905963 0.80 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL27325981 0.80 ESR1 (0.46) KMT2ARAB9AKDM4EALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 489 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118231660-A Positive electrode slurry, positive electrode plate and sodium ion battery 比亚迪股份有限公司 2024-06-21 CN claimed
WO-2024035194-A1 NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME 환인제약 주식회사 2024-02-15 WO claimed
CN-116670127-A EGFR inhibitors and compositions and uses thereof 贝达药业股份有限公司 2023-08-29 CN claimed
EP-3393472-A1 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR Merck Sharp & Dohme Corp. (US) 2018-10-31 EP claimed
WO-2017112556-A1 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME CORP. (US) 2017-06-29 WO claimed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US claimed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP claimed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US claimed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP claimed
WO-2008118758-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (GB) 2008-10-02 WO claimed
US-20070173548-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands CHIANG YUAN-CHING P 2007-07-26 US claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US claimed
US-20050209333-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands CHIANG YUAN-CHING P 2005-09-22 US claimed
US-20040077694-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands CHIANG YUAN-CHING P (US) 2004-04-22 US claimed
US-6664291-B2 Aromatic amidealkyl acid or ester or amide or hydroxy derivatives are useful in the treatment of obesity, overweight condition, hyperlipidemia, glucoma, cardiac arrhythmias, thyroid disease, skin disoders and diabetes PFIZER, INC. 2003-12-16 US claimed
US-20010051657-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands PFIZER INC. 2001-12-13 US claimed
US-20260109696-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2026-04-23 US disclosed
US-12590078-B2 2026-03-31 US disclosed
EP-0615977-A1 Spiro piperidines and homologs which promote release of growth hormone MERCK & CO. INC. (US) 1994-09-21 EP disclosed
WO-1994013696-A1 SPIRO PIPERIDINES AND HOMOLOGS WHICH PROMOTE RELEASE OF GROWTH HORMONE MERCK & CO., INC. (US) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590078-B2 ADRM1, USP19, USP1 KMT2A 2342/4885NPC1 3279/4885RAB9A 165/4885
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 KMT2A 1920/4885NPC1 897/4885RAB9A 2301/4885
US-20070173548-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands THRA, MC1R, TSHR KMT2A 3859/4885NPC1 1733/4885RAB9A 1947/4885
US-20050209333-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands THRA, MC1R, TSHR KMT2A 3859/4885NPC1 1733/4885RAB9A 1947/4885
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 KMT2A 4422/4885NPC1 4197/4885RAB9A 20/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 KMT2A 1920/4885NPC1 897/4885RAB9A 2301/4885
US-20260109696-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS KRAS, MYC, NRAS KMT2A 1898/4885NPC1 2234/4885RAB9A 620/4885
US-20040077694-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands THRA, MC1R, TSHR KMT2A 3893/4885NPC1 1575/4885RAB9A 1993/4885
US-20010051657-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands THRA, MC1R, THRB KMT2A 3863/4885NPC1 1456/4885RAB9A 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.